171 related articles for article (PubMed ID: 34461927)
1. Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients.
Zhao HF; Zhou XM; Wang J; Chen FF; Wu CP; Diao PY; Cai LR; Chen L; Xu YW; Liu J; Li ZY; Liu WL; Chen ZP; Huang GD; Li WP
J Transl Med; 2021 Aug; 19(1):372. PubMed ID: 34461927
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma].
Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643
[No Abstract] [Full Text] [Related]
3. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
4. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
[TBL] [Abstract][Full Text] [Related]
5. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
6. Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.
Bieńkowski M; Piaskowski S; Stoczyńska-Fidelus E; Szybka M; Banaszczyk M; Witusik-Perkowska M; Jesień-Lewandowicz E; Jaskólski DJ; Radomiak-Załuska A; Jesionek-Kupnicka D; Sikorska B; Papierz W; Rieske P; Liberski PP
PLoS One; 2013; 8(6):e65444. PubMed ID: 23762372
[TBL] [Abstract][Full Text] [Related]
7. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
[TBL] [Abstract][Full Text] [Related]
8. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
9. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile.
Lopez-Gines C; Gil-Benso R; Ferrer-Luna R; Benito R; Serna E; Gonzalez-Darder J; Quilis V; Monleon D; Celda B; Cerdá-Nicolas M
Mod Pathol; 2010 Jun; 23(6):856-65. PubMed ID: 20305620
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
[TBL] [Abstract][Full Text] [Related]
11. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
12. Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.
López-Ginés C; Navarro L; Muñoz-Hidalgo L; Buso E; Morales JM; Gil-Benso R; Gregori-Romero M; Megías J; Roldán P; Segura-Sabater R; Almerich-Silla JM; Monleón D; Cerdá-Nicolás M
Cell Oncol (Dordr); 2017 Aug; 40(4):389-399. PubMed ID: 28631186
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
Chen JR; Xu HZ; Yao Y; Qin ZY
Acta Neurol Scand; 2015 Nov; 132(5):310-22. PubMed ID: 25846813
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
17. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
[TBL] [Abstract][Full Text] [Related]
18. The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma.
Tini P; Pastina P; Nardone V; Sebaste L; Toscano M; Miracco C; Cerase A; Pirtoli L
Clin Neurol Neurosurg; 2016 Oct; 149():15-21. PubMed ID: 27450763
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of molecular biomarkers in glioblastoma.
Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
[TBL] [Abstract][Full Text] [Related]
20. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]